Strategic Partnerships vs. Acquisition: Governance Considerations
There is a particular moment in a clinical-stage company's life when two doors open at once. A large pharmaceutical company is interested in the lead asset, and it is not yet clear whether that interest will take the form of a licensing or co-development partnership or an outright acquisition of the company. Sometimes both are explicitly on the table. Sometimes the board has to decide which one to pursue before knowing what either would actually look like.
Boards tend to approach this as a comparison of outcomes: what would we get in a sale, what would we get in a partnership, which number is larger once properly risk-adjusted. That analysis is necessary and it is not sufficient, because the two options are not two prices for the same thing. They are two different futures for the company, with different risk profiles, different time horizons, different demands on the organization, and — most importantly from a governance standpoint — different distributions of benefit among the people sitting at the board table.
This article is about making that choice well: what each path actually commits the company to, why the decision is less symmetrical than it looks, and which conflicts predictably distort it.
The Two Paths Answer Different Questions
A sale converts the company into cash and, frequently, contingent consideration. It ends the enterprise as an independent entity, delivers liquidity to shareholders, resolves the question of future funding permanently, and transfers both the remaining risk and the remaining upside to the buyer. Whatever the asset ultimately becomes, it becomes it for someone else.
A partnership does something quite different. The company retains ownership of the asset while sharing the cost and risk of developing it, typically in exchange for upfront payment, development and regulatory milestones, and downstream royalties. The company stays independent, keeps a claim on the upside, and often gains a credible validator whose involvement makes the next financing easier. It also takes on an obligation to perform, cedes meaningful control over how the asset is developed, and continues to bear the risks of being a small company dependent on capital markets.
The crucial point for a board is that these are not substitutes offered at different prices. One resolves the company's future; the other extends it on altered terms. A board that evaluates them purely on risk-adjusted value is answering a narrower question than the one in front of it.
The Asymmetry Boards Miss
The most important structural feature of this decision is that it is not reversible in both directions, and the asymmetry does not run the way most boards assume.
The intuitive framing is that partnering preserves optionality — the company can always sell later, so partner now and keep the sale available. There is real truth in this. A partnership that de-risks the asset, brings in non-dilutive capital, and validates the science can make the company substantially more valuable and more sellable than it is today. Partnering first and selling later is a well-worn path, and for many companies it is the right one.
But the preserved option is usually narrower than it appears, for reasons that live in the partnership agreement itself. A partner may hold rights of first negotiation or refusal over the asset or the company. The agreement may contain change-of-control provisions that give the partner rights, or trigger consequences, if the company is acquired. Exclusivity in a territory or field constrains what a future buyer actually acquires. And at a more basic commercial level, a partnered asset is simply worth less to an acquirer than an unpartnered one, because the buyer is purchasing a company that has already given away a share of the economics and a measure of control over the program they most want.
There is a further, subtler effect: the partner itself frequently becomes the most natural acquirer, and everyone involved knows it. That can be good — partnerships do convert into acquisitions regularly, and a partner who has lived with the asset through a development cycle is an informed and motivated buyer. But it also means that after signing, the universe of plausible acquirers often narrows toward one, and a process with one realistic bidder is a weaker negotiating position than a process with four.
So the honest version of the asymmetry is this: a sale forecloses the partnership absolutely, while a partnership usually preserves a constrained and somewhat devalued version of the sale. That still favors partnering in many cases. But a board should make the comparison with the constraints visible rather than assuming it keeps full freedom.
The Conflicts That Shape the Choice
This decision activates divergent interests more reliably than almost any other, and they rarely announce themselves.
Investor liquidity timing. A fund approaching the end of its life, or managing portfolio-level pressures, has reasons to prefer a sale that produces distributable proceeds now over a partnership that produces milestone payments to a company the fund still has to hold. That preference can be entirely rational for the fund and still diverge from what maximizes value for shareholders as a whole. Boards should be alert to the investor director who is consistently drawn to the exit without a value-based argument for it, and equally to the one who resists an attractive sale because the fund's mark would suffer.
Management's two very different futures. In a sale, executives typically face a change-of-control payout and an uncertain or terminating role. In a partnership, they keep running the company, continue to draw salaries, and preserve the possibility of a larger outcome later. Depending on the specifics, management may be materially better off under one path than the other, and they are the people doing the analysis the board will rely on. This is not an accusation; it is a structural feature that the board should name and account for, ideally by knowing the terms of management's change-of-control arrangements before weighing management's recommendation.
The founder's attachment. Partnering lets the company continue; selling ends it. For founders, that difference is rarely neutral, and the preference for continuation can present itself as a confident valuation argument.
Preferred and common, again. As in any exit decision, liquidation preferences mean a given sale price can be excellent for preferred holders and nearly worthless for common. The partnership path, which defers the exit in hope of a larger one, can therefore look very different to the two constituencies — sometimes making common holders the natural advocates for partnering and preferred holders the advocates for selling, each for reasons that have nothing to do with the merits.
None of these conflicts makes anyone a bad actor. What they do mean is that a board which simply polls the room and goes with the sentiment is likely aggregating interests rather than judgment.
The Questions That Do the Work
What is this asset worth if we execute well, and how likely is that? Both paths require a view on the asset's eventual value. The partnership path is a bet that the company can capture more of that value by staying in the game; the sale is a decision to take a discounted certain-ish amount now. The board cannot evaluate either without an honest, probability-weighted view of the destination, and should be suspicious of an analysis in which the partnered path's expected value exceeds the sale by a comfortable margin — that margin is usually where the optimism is hiding.
Can we actually execute the partnered path? A partnership is an operating commitment, not a financing. The company will owe deliverables, participate in joint governance structures, manage an alliance with a counterparty many times its size, and continue to fund its share. Boards routinely underestimate how much management attention alliance management consumes and how different it is from running an independent program. If the company lacks the organizational depth to hold up its end, the partnership will underdeliver and the milestones will not arrive.
What does the partnership do to our freedom? Specifically: what rights does the partner get over a change of control, what exclusivity are we granting, what happens to the agreement if we are acquired, and how does all of that affect what a future buyer is purchasing? These provisions are where the future option is quietly priced, and they deserve board-level attention rather than being left entirely to deal counsel.
Do we still need to raise, and on what terms? A partnership's upfront payment extends runway but rarely eliminates the need for equity. The board should understand what the financing picture looks like on the partnered path — whether the validation makes the next round materially easier, and what happens if the partner's enthusiasm cools and the market reads that as a signal.
What happens if the partner disengages? Large companies reprioritize. A partner can deprioritize a program without terminating it, leaving the asset encumbered and stalled — arguably the worst outcome available, since the company has given up economics and control and received neither progress nor liquidity. The board should understand what diligence obligations the partner has, what rights the company has if the partner goes quiet, and how the asset returns if things end.
Are we comparing like with like on contingency? Both paths typically deliver much of their value contingently — milestones and royalties in a partnership, earn-outs or contingent value rights in a sale. The headline numbers are not comparable without risk-adjusting both, and the question of who controls the effort required to hit the milestones matters enormously in each case.
The Traps
Treating the partnership as the cautious choice. Partnering feels moderate — nobody is selling the company, everyone keeps their job, the story continues. But a partnership on poor terms with a disengaged partner can destroy more value than an unexciting sale, and it does so slowly enough that no one has to take responsibility for it. Continuation is not the same as prudence.
Letting the partner's interest substitute for a market test. One large company's interest tells the board that the asset is attractive. It does not tell the board what the asset is worth, and a company that negotiates with a single interested party on either path is negotiating without leverage. Where a sale is genuinely under consideration, the board should want to know whether other buyers exist before concluding that this one's offer is the measure of value.
Deciding under runway pressure. A company with nine months of cash does not have a real choice between these paths; it has whichever one can close in time. The decision is only genuinely available to a board that has preserved enough runway to walk away from both, which is a reason to engage the question earlier than it feels necessary.
Accepting management's framing without examining the incentives behind it. Not because management is untrustworthy, but because the board is the only body positioned to notice that the recommendation and the recommender's interests happen to coincide.
Ignoring the organization's view. A partnership that the scientific team believes will subordinate their program to a partner's priorities, or a sale that will disperse the team, has consequences for execution either way. The board need not defer to internal sentiment, but it should know what it is.
The Underlying Principle
When both doors are open, the board's task is not to pick the larger number. It is to decide what kind of risk the company's shareholders should be holding — a resolved outcome at a discount, or a continued, shared, partially-controlled claim on a larger one — and to make that decision knowing that the people around the table have materially different stakes in the answer.
The discipline that produces a good decision is mostly about seeing clearly: understanding that the two paths are not symmetrical, that the preserved option after partnering is narrower and cheaper than it appears, that the partnership is an operating commitment the company must actually be able to meet, and that the enthusiasm in the room is not evenly distributed by accident.
A board that works through those things can choose either path with confidence. A board that compares two risk-adjusted numbers and takes the bigger one has done the arithmetic and skipped the decision.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.